Click chemistry enables rapid development of potent sEH PROTACs using a direct-to-biology approach
The direct-to-biology (D2B) approach enables biological screening of crude reaction mixtures, eliminating the need for purification steps and thereby accelerating drug discovery. In this study, we developed a miniaturized D2B platform for the rapid synthesis of proteolysis targeting chimera (PROTAC) degraders of soluble epoxide hydrolase (sEH). We used copper-catalyzed azide-alkyne cycloaddition and optimized the conditions for 384-well PCR plate applications with 10 μL reaction volumes on a 300 nmol scale. This approach enabled the D2B synthesis of 92 crude PROTACs from azide-functionalized CRBN-ligands and alkyne-linked sEH inhibitors. Biological screening using a HiBiT lytic degradation assay identified two hits that were resynthesized and exhibited subnanomolar DC<sub>50</sub> values and degradation efficacy (D<sub>max</sub>). Thus, we established a scalable, cost-effective and time-saving D2B platform for the discovery of PROTACs in very small quantities. This methodology is particularly suitable for early-stage screening and hit validation assessing the degradability of a target.
Authors
- Ewgenij Proschak (ORCID: https://orcid.org/0000-0003-1961-1859)
- Kerstin Hiesinger (ORCID: https://orcid.org/0000-0001-5458-816X)
- Stefan Knapp (ORCID: https://orcid.org/0000-0001-5995-6494)
- Steffen Brunst
- Aimo Kannt (ORCID: https://orcid.org/0000-0002-5197-2286)
- Lilia Weizel (ORCID: https://orcid.org/0000-0002-0373-2114)
- Nick Liebisch
- Julia Schönfeld
Institutions
- Goethe University Frankfurt (DE)
- Frankfurt Institute for Advanced Studies (DE)
- Structural Genomics Consortium (CA)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
Publication Details
- Journal
- Chemical Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5cc03325j
- Citations
- 3
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Deutsche Forschungsgemeinschaft
- Fraunhofer-Gesellschaft
- Deutsche Krebshilfe